MedPath

Fentanyl

Generic Name
Fentanyl
Brand Names
Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
Drug Type
Small Molecule
Chemical Formula
C22H28N2O
CAS Number
437-38-7
Unique Ingredient Identifier
UF599785JZ

Overview

Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.

Background

Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.

Indication

Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients. Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.

Associated Conditions

  • Cancer Related Pain (Breakthrough Pain)
  • Severe, Chronic Pain

FDA Approved Products

SUBSYS
Manufacturer:Insys Therapeutics, Inc.
Route:SUBLINGUAL
Strength:0.2 mg in 1 1
Approved: 2021/05/04
NDC:20482-002
FENTANYL
Manufacturer:Apotex Corp.
Route:TRANSDERMAL
Strength:12 ug in 1 h
Approved: 2023/05/01
NDC:60505-7080
FENTANYL
Manufacturer:Quality Care Products, LLC
Route:TRANSDERMAL
Strength:50 ug in 1 h
Approved: 2023/07/13
NDC:55700-748
FENTANYL
Manufacturer:Quality Care Products, LLC
Route:TRANSDERMAL
Strength:25 ug in 1 h
Approved: 2023/07/13
NDC:55700-753
FENTANYL
Manufacturer:Apotex Corp.
Route:TRANSDERMAL
Strength:75 ug in 1 h
Approved: 2023/05/01
NDC:60505-7083

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath